65,437 trials
Neovascular Age-related Macular Degeneration
Primary: Average Change in Visual Acuity (Letters) From Month 3 to Month 4 Through Month 12 — 3.3; 1.7 Letters
Diabetic Peripheral Neuropathy
Primary: Change in Patient Quality of Life at Baseline and 8 Months — 0.66; 0.65; 0.68; 0.68 units on a scale
Contrast Enhanced Computed Tomography (CT) Scanning
Primary: Image Quality as Assessed by Ratio of Tissue Density of Main Portal Vein (MPV) to the Aorta — 0.95; 0.95 Ratio
Asthma
Primary: Standardized Baseline-adjusted Trough Morning Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks…
Tachycardia
Primary: Patients With Inappropriate Shock(s) — 1.4 Percentage of pts with inap shocks
Anaemia
Primary: Change From Baseline (CFB) in Hemaglobin (Hgb) at Week 4 — -1.52; -0.29; -0.02; 0.60 grams/deciliter (g/dL)
Pre-diabetes · Impaired Fasting Glucose · Impaired Glucose Tolerance
Primary: Insulin Sensitivity — 1835.4; 1846.0 ratio without units — p=.983
Diabetes Mellitus · Diabetes Mellitus, Type 2 · Glucose Metabolism Disorders
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 0; 0; 0; 0 participants
Primary Open Angle Glaucoma
Primary: Complication Rates — 29; 28 Participants — p=0.7
HIV Infections
Primary: Antepartum Component: Number of Confirmed Infant HIV Infections — 25; 7; 2 Participants
Pregnancy
Primary: Number of Recruited Eligible Pregnant Women <20 Weeks Gestational Age — 166 Participants
Breast Cancer
Primary: Number of Participants With Worsening of Musculoskeletal Symptoms (MS) — 23; 18; 24; 18 participants
Cystic Fibrosis
Primary: Number of Participants With Treatment Emergent Adverse Events. — 14; 13; 15; 21 Participants
Metastatic Melanoma · Cutaneous Melanoma
Primary: Median Progression-free Survival (PFS) With 95% Confidence Intervals — 1.93; 2.53 months
Obesity
Primary: %TBWL — -18.0 % TBWL